BNGO Key Statistics, Chart & Performance
The current stock price of BNGO is 1.52 USD. In the past month the price decreased by -16.02%. In the past year, price decreased by -87.94%.
BNGO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.93 | 218.19B | ||
| DHR | DANAHER CORP | 29.87 | 162.69B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 185.88 | 56.48B | ||
| A | AGILENT TECHNOLOGIES INC | 24.8 | 39.23B | ||
| IQV | IQVIA HOLDINGS INC | 19.51 | 38.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.94 | 29.01B | ||
| WAT | WATERS CORP | 30.4 | 22.98B | ||
| ILMN | ILLUMINA INC | 30.95 | 20.62B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.8 | 19.73B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.69 | 15.99B | ||
| TEM | TEMPUS AI INC | N/A | 11.15B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B |
Related stock screener links
About BNGO
Company Profile
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The company is headquartered in San Diego, California and currently employs 98 full-time employees. The company went IPO on 2018-08-01. The firm offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. The company also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The firm additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The firm markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
Company Info
BIONANO GENOMICS INC
9540 Towne Centre Drive, Suite 100
San Diego CALIFORNIA 92121 US
CEO: R. Erik Holmlin
Employees: 98
Phone: 18588887600
BIONANO GENOMICS INC / BNGO FAQ
What does BNGO do?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The company is headquartered in San Diego, California and currently employs 98 full-time employees. The company went IPO on 2018-08-01. The firm offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. The company also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The firm additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The firm markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
What is the current price of BNGO stock?
The current stock price of BNGO is 1.52 USD.
What is the dividend status of BIONANO GENOMICS INC?
BNGO does not pay a dividend.
What is the ChartMill rating of BIONANO GENOMICS INC stock?
BNGO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for BIONANO GENOMICS INC?
BIONANO GENOMICS INC (BNGO) operates in the Health Care sector and the Life Sciences Tools & Services industry.
What is the employee count for BNGO stock?
BIONANO GENOMICS INC (BNGO) currently has 98 employees.
When does BIONANO GENOMICS INC (BNGO) report earnings?
BIONANO GENOMICS INC (BNGO) will report earnings on 2026-03-30, after the market close.
BNGO Technical Analysis
BNGO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BNGO. BNGO has a bad profitability rating. Also its financial health evaluation is rather negative.
BNGO Financial Highlights
Over the last trailing twelve months BNGO reported a non-GAAP Earnings per Share(EPS) of -20.56. The EPS increased by 77.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.79% | ||
| ROE | -163.82% | ||
| Debt/Equity | 0.08 |
BNGO Forecast & Estimates
For the next year, analysts expect an EPS growth of 92.3% and a revenue growth -2.24% for BNGO